Therapeutic potential of GLP-1 for treatment of diabetes

Abstract

Glucose homeostasis are primarily controlled by two indigenous peptides namely insulin and glucagon. In addition to insulin and glucagon several other endogenous substances are discovered that directly or indirectly control glucose metabolism. Diabetes is a metabolic disease which is caused by a deficiency of insulin or by improper functioning of insulin signaling. There are therapies which are used to cure diabetes but they are associated with limitations like they cause hypoglycemia and do not improve the health of beta cells. But with the discovery of incretin hormones like GIP and GLP-1 diabetes progression may be prevented as both of the peptides show insulinotropic activity and demonstrated that GLP-1 is primarily responsible for stimulation of insulin secretion GLP-1 stimulate insulin secretion dependent of glucose concentration and have potential long-term ability to improve the β-cell function, therefore the potential ability of the GLP-1 drug class may be helpful in delaying or perhaps even preventing diabetes progression.